Saluda

IPO

Homepage - Saluda Medical US

Public · Macquarie Park, Australia · Founded 2011 · $375.0M raised

Headquarters
Macquarie Park
Founded
2011
Business Model
B2B
Total Funding
$375.0M
Last Round
$100.0M Growth EquityJan 2025
Rounds
5
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Saluda Medical develops the Evoke® System, the world's first closed-loop spinal cord stimulation (SCS) platform for chronic pain treatment. Founded in 2011 in Australia, the company pioneered Evoked Compound Action Potential (ECAP) sensing technology that objectively measures the spinal cord's neural response to stimulation and automatically adjusts therapy on every pulse — replacing open-loop guesswork with precise, biomarker-driven neuromodulation. The Evoke System received FDA premarket approval in 2022 and the EVA automated programming platform launched in the US in 2025. With over $664M raised and clinical results published in The Lancet Neurology and JAMA Neurology, Saluda is redefining the standard of care for intractable chronic pain of the trunk and limbs.

Summary

Saluda is a Biotech company based in Macquarie Park, Australia, founded in 2011. It has raised $375.0M in total across 5 rounds, most recently a $100.0M Growth Equity round in Jan 2025. Investors include Wellington Management, Redmile Group and Boston Scientific Corporation.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

IPODec 2025
$150.0M

Sign up to see all 6 events

Funding: Series A through Growth Equity. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Saluda on Indexed.vc
<a href="https://indexed.vc/companies/saluda"><img src="https://indexed.vc/api/badge/company/saluda" alt="Saluda on Indexed.vc" width="260" height="76" /></a>